Related Experiment Video

Updated: Jul 20, 2026

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic

Karsten Wursthorn1, Marc Lutgehetmann, Maura Dandri

  • 1Department of Medicine, University Hospital Hamburg-Eppendorf, Hamburg, Germany.

Hepatology (Baltimore, Md.)
|August 31, 2006
PubMed

Insights

Combination therapy using pegylated interferon alpha-2b (peg-IFN) and adefovir dipivoxil (ADV) significantly reduced Hepatitis B virus (HBV) covalently closed circular DNA (cccDNA) and serum HBV-DNA levels in chronic hepatitis B (CH-B) patients.

Area of Science:

  • Hepatology
  • Virology
  • Immunology

Background:

  • Hepatitis B virus (HBV) covalently closed circular DNA (cccDNA) is the primary driver of persistent infection in hepatocytes.
  • Understanding cccDNA dynamics during antiviral therapy is crucial for managing chronic hepatitis B (CH-B).

Purpose of the Study:

  • To evaluate changes in intrahepatic cccDNA during 48 weeks of combination antiviral therapy.
  • To correlate these changes with virological, biochemical, and histological parameters in CH-B patients.

Main Methods:

  • Twenty-six HBsAg-positive CH-B patients received 48 weeks of pegylated interferon alpha-2b (peg-IFN) and adefovir dipivoxil (ADV).
  • Paired liver biopsies before and after treatment were analyzed for intrahepatic HBV-DNA, including cccDNA.
  • Serum HBV-DNA, HBsAg, HBeAg, ALT levels, and antibody status were monitored.

Main Results:

  • Significant reductions in median serum HBV-DNA (-4.9 log10) and intrahepatic total HBV-DNA (-2.2 log10) and cccDNA (-2.4 log10) were observed.
  • Intrahepatic HBV-DNA changes correlated positively with serum HBsAg reduction.
  • HBeAg loss or anti-HBe seroconversion occurred in 8/15 patients, associated with lower cccDNA levels.

Conclusions:

  • Combination therapy with peg-IFN and ADV effectively reduces serum and intrahepatic HBV-DNA, including cccDNA.
  • Therapy-induced reductions in cccDNA correlate with virological and serological markers of treatment response.
  • Observed decreases in antigen-positive hepatocytes suggest cytolytic mechanisms contribute to treatment efficacy.

More Related Videos

Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix10:37

Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix

Published on: October 20, 2021

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Antiviral Nucleoside Inhibitors01:22

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
Inhibitors Of Virion Release01:25

Inhibitors Of Virion Release

Viral replication and dissemination rely on efficient mechanisms for host cell entry, genome replication, assembly, and release. Influenza viruses, such as types A and B, are negative-sense single-stranded RNA viruses with a segmented genome, that depend on two critical surface glycoproteins to carry out these processes: hemagglutinin (HA) and neuraminidase (NA). HA initiates infection by binding to sialic acid residues on the surface of host epithelial cells, facilitating receptor-mediated...